Objective: To evaluate the efficacy and safety of sparfloxacin in the treatment of bacterial infections.
Methods: A randomized controlled multi-centre clinical trial was conducted. Ofloxacin used as the control drug. A total of 212 patients entered the study, with 106 in the sparfloxacin group and the remaining 106 in the ofloxacin group. Both compounds were given by oral administration.
Results: The cure rate of sparfloxacin and ofloxacin was 74.5% and 69.8% respectively and the overall efficacy rate was 91.5% and 88.7% respectively. The bacterial clearance rate was 90.7% in the sparfloxacin group and 90.8% in the ofloxacin group. The adverse drug reaction rate of sparfloxacin and ofloxacin was 9.43% and 8.49% respectively. There was no statistical significant difference between the two groups for the above results. The results of in vitro activity of sparfloxacin as compared with other 5 antibacterial agents showed that sparfloxacin had good activity against many Gram-negative organisms and was similar to those of ofloxacin. The activity against Gram-positive organisms (MIC(90) <or= 0.25 mg/L) was generally higher than that of ofloxacin.
Conclusion: Sparfloxacin is a highly effective and safe broad-spectrum antibacterial agent for the treatment of bacterial infections. It is also effective in the treatment of infections caused by Gram-positive organisms.